CClinicalTrials.gg
RecruitingNCT04114994BoCAUpdated Aug 1, 2024

Longitudinal Cognitive Assessment by BoCA

An observational study in Alzheimer Disease, Mild Cognitive Impairment and Vascular Dementia, sponsored by Alzheimer's Light LLC. Recruiting at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Alzheimer's Light LLC · Observational

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
50 Years and older
Sex
All
01

Study summary

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

Read the detailed description

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not- repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.

After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts.

The BoCA evaluation can help doctors figure out if an underlying condition is causing a patient's cognitive decline. Many treatable conditions such as sleep disorders, mood problems, heavy metal accumulation, as well as lack of movement and social interactions can affect memory and thinking.

Our goal is to reduce barriers for patients to receive the testing that may benefit their treatment and health through the use of digital technology.

02

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment
  • Vascular Dementia
  • Frontotemporal Dementia
  • Parkinson Disease
  • Multiple Sclerosis
  • TBI
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 96 across 1,057 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

This is the only study on the registry with Alzheimer's Light LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

According to the American Academy of Neurology, nearly 7% of people in their early 60s worldwide have mild cognitive impairment, while the condition affects 38% of people ages 85 and older.

The BoCA evaluation can help doctors figure out if an underlying condition is causing a patient's cognitive decline. Many treatable conditions such as sleep disorders, mood problems, heavy metal accumulation, as well as lack of movement and social interactions can affect memory and thinking.

Our goal is to reduce barriers for patients to receive the testing that may benefit their treatment and health through the use of digital technology.

Inclusion criteria

age 50 or older

Exclusion criteria

Exclusion Criteria:

younger than 50 years

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alzheimer's Disease

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • Mild Cognitive Impairment

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • Frontotemporal Dementia

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • Vascular Dementia

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • Parkinson Disease

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • Traumatic Brain Injury (TBI)

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • Multiple Sclerosis

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

  • No diagnosis

    Diagnostic Test: Boston Cognitive Assessment (BoCA)

Interventions

  • Diagnostic testBoston Cognitive Assessment (BoCA)

    The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals. BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance. After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts.

06

What researchers measure

Primary outcomes

  1. Boston Cognitive Assessment (BoCA)

    The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Andrey Vyshedskiy
    Miami, Florida 33156, United States
    • Andrey Vyshedskiy · Contact · vysha@bu.edu · 617-433-8577
    Recruiting
08

References and documents

Publications

  • Foster NL, Bondi MW, Das R, Foss M, Hershey LA, Koh S, Logan R, Poole C, Shega JW, Sood A, Thothala N, Wicklund M, Yu M, Bennett A, Wang D. Quality improvement in neurology: Mild cognitive impairment quality measurement set. Neurology. 2019 Oct 15;93(16):705-713. doi: 10.1212/WNL.0000000000008259. Epub 2019 Sep 18. No abstract available. PubMed 31534026 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04114994
Lead sponsor
Alzheimer's Light LLC
Responsible party
Sponsor
First posted
Oct 3, 2019
Start date
Oct 1, 2019
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Aug 1, 2024

Study contacts

ANDREY VYSHEDSKIY, Ph.D.
Contact
vysha@bu.edu
6174338577

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion